

Sponsored By:



EFFECT OF SINGLE ORAL DOSES OF BGG492 IN THE PHOTOSENSITIVITY MODEL

Dorothee Kasteleijn-Nolst Trenité¹, Bernard Steinhoff², Christian Brandt³, Thomas Mayer⁴, Felix Rosenow⁵, Georges Imbert⁶, Klaus Kucher⁶.

1. Utrecht, The Netherlands
2. Kehl-Kork, Germany
3. Bielefeld, Germany
4. Radeberg, Germany
5. Marburg, Germany
6. Novartis Institutes for BioMedical Research, Basel, Switzerland.

BGG492 is a competitive AMPA receptor antagonist with a good affinity for rat and human native AMPA receptors. A number of data support the link between AMPA receptors and epilepsy. BGG492 is orally active in all tested seizure models. Data from the kindling development model indicate that BGG492 has a putative therapeutic potential as an anti-epileptogenic drug.

A multicenter, single-blind, within-subject, placebo-controlled proof of concept study was performed to assess the effect of single oral doses of BGG492 on the photoparoxysmal EEG response in patients with photosensitive epilepsy. Results will be discussed.